FSW WORLDWIDE
- Thread starter js555
- Start date
I sent the webform in the month of october. As of now I also get the same generic afghanistan reply.
Hi, agamsingh3279!
I think many of us have never received anything close to the message you got. Just generic mails about COVID and Afghan refugees… Could you specify what exactly you wrote in the web form which led to such a detailed info about various verification stages? I guess the word choice is key for web form queries.
guelphite
Hero Member
- Jan 22, 2021
- 303
- Category........
- FSW
- NOC Code......
- 2173
- AOR Received.
- 28-10-2020
- Med's Request
- 03-12-2020
- Med's Done....
- 07-01-2020
You sent a webform and got a very detailed reply from IRCC and then you started sending again another webform?
Why the hell ? You got the response, now wait a damn bit please.
Sometimes I give IRCC all the right to act in any kind of way they see fit, I mean with these kind of demands, who wouldn't ?
This ain't it.
Applicants have, and are afforded the expectation to a reasonable response to their queries about their application. It was a webform, it isn't like that person called IRCC, got an answer, then immediately called back again to request more information (not that there would be anything wrong with that anyway)
You can stop licking their boot.
Merck to make its COVID-19 antiviral pill in Canada, company announces
Merck is partnering with a pharmaceutical company in Ontario to make its oral COVID-19 antiviral pill in Canada.
Merck, the maker of molnupiravir — which is still under Health Canada review — announced Monday it has reached an agreement with Thermo Fisher Scientific in Whitby to manufacturer its treatment.
Marwan Akar, president and managing director with Merck Canada Inc., told reporters at a news conference that Thermo Fisher will make molnupiravir for distribution in Canada and the United Kingdom, as well as for European, Asian Pacific and Latin American countries pending approvals in those countries.
“Make no mistake, vaccines remain our primary and first line of defence, but we need new tools in the toolbox, and antivirals provide just that,” Akar said.
“This is another way to combat this pandemic, help save lives, accelerate patient recovery and avoid hospitalizations.”
Merck’s announcement comes on the heels of the federal government’s recent agreement with the company to purchase 500,000 courses of its molnupiravir treatment, with an option to add 500,000 more pending approval.
The federal government has also announced a deal with Pfizer to purchase one million courses of its oral antiviral treatment, PF-07321332, pending Health Canada approval.
“As soon as these drugs are authorized for use, the government will work on getting them to provinces and territories as quickly as possible so that health-care providers can help Canadians who need them most,” Filomena Tassi, Canada’s minister of public services and procurement, said Friday.
Merck’s pill is still under review by Health Canada as the company continues its rolling submission.
Recently, Merck shared data suggesting its drug was significantly less effective than previously thought, reducing hospitalizations and deaths in high-risk individuals by around 30 per cent.
The treatment has received approval in the United Kingdom.
Cardiologist and epidemiologist Dr. Christopher Labos previously told Global News that antiviral pills could potentially limit the strain of COVID-19 on Canada’s health-care system by reducing the effects of the virus, but they don’t “prevent the problem.”
“It just treats the problem,” he said. “In terms of preventing outbreaks, vaccines are clearly the better course of action.”
— with files from Reuters and Global News’ Eric Stober
Merck is partnering with a pharmaceutical company in Ontario to make its oral COVID-19 antiviral pill in Canada.
Merck, the maker of molnupiravir — which is still under Health Canada review — announced Monday it has reached an agreement with Thermo Fisher Scientific in Whitby to manufacturer its treatment.
Marwan Akar, president and managing director with Merck Canada Inc., told reporters at a news conference that Thermo Fisher will make molnupiravir for distribution in Canada and the United Kingdom, as well as for European, Asian Pacific and Latin American countries pending approvals in those countries.
“Make no mistake, vaccines remain our primary and first line of defence, but we need new tools in the toolbox, and antivirals provide just that,” Akar said.
“This is another way to combat this pandemic, help save lives, accelerate patient recovery and avoid hospitalizations.”
Merck’s announcement comes on the heels of the federal government’s recent agreement with the company to purchase 500,000 courses of its molnupiravir treatment, with an option to add 500,000 more pending approval.
The federal government has also announced a deal with Pfizer to purchase one million courses of its oral antiviral treatment, PF-07321332, pending Health Canada approval.
“As soon as these drugs are authorized for use, the government will work on getting them to provinces and territories as quickly as possible so that health-care providers can help Canadians who need them most,” Filomena Tassi, Canada’s minister of public services and procurement, said Friday.
Merck’s pill is still under review by Health Canada as the company continues its rolling submission.
Recently, Merck shared data suggesting its drug was significantly less effective than previously thought, reducing hospitalizations and deaths in high-risk individuals by around 30 per cent.
The treatment has received approval in the United Kingdom.
Cardiologist and epidemiologist Dr. Christopher Labos previously told Global News that antiviral pills could potentially limit the strain of COVID-19 on Canada’s health-care system by reducing the effects of the virus, but they don’t “prevent the problem.”
“It just treats the problem,” he said. “In terms of preventing outbreaks, vaccines are clearly the better course of action.”
— with files from Reuters and Global News’ Eric Stober
Copied from Telegram:
Category EE : PNP (SINP), EE
AOR: 8 Oct 2020
COR(country of residence): India
Medicals(day of first medicals): 07 oct 2020
Re medicals request : 01 Nov 2021
Re medical done :09 Nov 2021
Re medical passed: 17 Nov 2021
Primary Visa office : CIO
Secondary visa office - Ottawa
PPR: 06 December 2021
Category EE : PNP (SINP), EE
AOR: 8 Oct 2020
COR(country of residence): India
Medicals(day of first medicals): 07 oct 2020
Re medicals request : 01 Nov 2021
Re medical done :09 Nov 2021
Re medical passed: 17 Nov 2021
Primary Visa office : CIO
Secondary visa office - Ottawa
PPR: 06 December 2021
Copied from Telegram:
Just got RFV mail
Dec 2020 AOR
Remedical passed on 27 Nov
PPR - 6 December
VO-CIO
OINP
Just got RFV mail
Dec 2020 AOR
Remedical passed on 27 Nov
PPR - 6 December
VO-CIO
OINP